title: [Treatment of hypertension with indapamide 1.5 mg sustained-release form: synthesis of results].
abstract: In accordance with international recommendations on the need to decrease doses of antihypertensive drugs, a low-dose (1.5 mg) sustained-release form of indapamide was developed so as to optimize the safety/efficacy ratio, while maintaining a once-daily administration. The new formulation ensures that the active ingredient release occurs in a sustained manner over 24 hours, with mean concentrations close to the maximal concentration over a prolonged period, while avoiding peak plasma concentrations. Clinical data were obtained mainly through two European multicenter, randomized, double-blind trials, totalling 690 patients. Firstly, the antihypertensive efficacy' of the new indapamide 1.5 mg form was demonstrated by measuring blood pressure 24 hours after the last drug intake, using a mercury sphygmomanometer; the equivalence of its antihypertensive efficacy with the immediate-release form of indapamide 2.5 mg was then verified. Biochemical safety data showed better acceptability with indapamide 1.5 mg with in particular a reduction of more than 50% of the number of patients with kalemia < 3.4 mmol/l; clinical safety data confirmed the good acceptability observed with the 2.5 mg immediate-release form of indapamide since many years, especially regarding glucose and lipid neutrality. In conclusion, the 1.5 mg sustained-release form of indapamide has an improved antihypertensive efficacy/safety ratio which is in accordance with international recommendations for the usage of low doses of antihypertensive drugs and diuretics in the first-line treatment of hypertension.
authors.affiliation: Institut de Recherches internationales Servien, Courbevole.
authors.forename: D
authors.initials: D
authors.lastname: Guez
authors.forename: J M
authors.initials: JM
authors.lastname: Mallion
authors.forename: J P
authors.initials: JP
authors.lastname: Degaute
authors.forename: P L
authors.initials: PL
authors.lastname: Malini
authors.forename: R
authors.initials: R
authors.lastname: Baldwin
authors.forename: D
authors.initials: D
authors.lastname: Rodriguez-Pujol
authors.forename: A
authors.initials: A
authors.lastname: de Cordoüe
authors.forename: S
authors.initials: S
authors.lastname: Barrandon
authors.forename: C
authors.initials: C
authors.lastname: Chastang
authors.forename: M
authors.initials: M
authors.lastname: Safar
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007008:Hypokalemia / Q000209:etiology; D007190:Indapamide / Q000097:blood / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D003692:Delayed-Action Preparations; D007190:Indapamide
vernacular_title: Traitement de l'hypertension artérielle par l'indapamide 1,5 mg comprimé enrobé à libération prolongée: synthèse des résultats.